Related Experiment Video

Updated: Apr 21, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for

Ju-Hee Lee1, Kyung Hee Jung1, Hyunseung Lee1

  • 1Department of Drug Development, College of Medicine, Inha University, Incheon, Republic of Korea.

Oncotarget
|October 23, 2014
PubMed

Insights

Researchers developed HS-133, a fluorescent PI3K inhibitor, for breast cancer. This novel agent suppresses tumor growth, induces apoptosis, and allows in vivo imaging, showing promise as a targeted anticancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Phosphoinositide 3-kinase/Akt (PI3K/Akt) signaling is crucial in numerous human cancers.
  • Monitoring drug distribution is vital for targeted cancer therapy and assessing treatment response.
  • Developing novel therapeutic agents with imaging capabilities is a key area in cancer research.

Purpose of the Study:

  • To develop novel xanthine derivatives as dual-function agents inhibiting PI3K and exhibiting fluorescence.
  • To evaluate the anticancer efficacy and biodistribution of a lead compound, HS-133.
  • To explore HS-133 as a potential fluorescent anticancer agent for breast cancer.

Main Methods:

  • Synthesis and characterization of xanthine derivatives.
  • In vitro assays for PI3K inhibition, anti-proliferative effects, apoptosis induction, and cell cycle analysis.
  • Western blotting for key pathway proteins (e.g., cleaved PARP, caspases, HIF-1α, VEGF).
  • Endothelial cell assays for tube formation and migration.
  • In vivo fluorescence imaging and tumor growth inhibition studies in mouse xenograft models.

Main Results:

  • HS-133 demonstrated potent PI3K inhibition and anti-proliferative activity.
  • HS-133 induced G0/G1 cell cycle arrest and apoptosis via caspase activation.
  • HS-133 suppressed angiogenesis-related factors (HIF-1α, VEGF) and endothelial cell functions.
  • In vivo imaging confirmed HS-133 localization in tumors, and oral administration inhibited tumor growth in a breast cancer xenograft model.

Conclusions:

  • HS-133 is a novel fluorescent PI3K inhibitor with significant anticancer activity.
  • HS-133 exhibits dual functionality, enabling therapeutic intervention and in vivo tumor visualization.
  • HS-133 shows potential as a targeted fluorescent anticancer agent for human breast cancer treatment.

More Related Videos

Single-molecule Super-resolution Imaging of Phosphatidylinositol 4,5-bisphosphate in the Plasma Membrane with Novel Fluorescent Probes07:26

Single-molecule Super-resolution Imaging of Phosphatidylinositol 4,5-bisphosphate in the Plasma Membrane with Novel Fluorescent Probes

Published on: October 15, 2016

10.9K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.0K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.3K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
12.0K